Hormonal IUD (Mirena/Kyleena) Side Effects: Real Incidence Rates From Clinical Trials

What the Trial Data Actually Show About Side-Effect Incidence

Clinical trial data on levonorgestrel IUDs are more detailed than most patients realize. The two key registration studies for Mirena enrolled thousands of women, and a dedicated Phase III trial for Kyleena enrolled 1,452 women across North America and Europe. The numbers below come from those sources and from post-market surveillance, not from anecdote.

Bleeding and Spotting: The Most Reported Complaint

Irregular bleeding is the side effect most likely to make a woman consider removal. In the Mirena registration studies submitted to the FDA, approximately 70% of users experienced unscheduled bleeding or spotting in the first three months. By month six, that figure dropped substantially. By 12 months, about 20% of Mirena users reported no bleeding at all (amenorrhea), rising to roughly 50% by year five.

Kyleena, which releases a lower hormone dose (approximately 17.5 mcg per day initially vs. Mirena's 20 mcg per day), produces less amenorrhea. In the Kyleena Phase III trial, 12% of users were amenorrheic at one year, compared with roughly 20% for Mirena. For women who prefer to keep some monthly bleeding as a hormonal reassurance signal, this difference matters.

Cramping and Pelvic Pain at Insertion

Insertion pain is predictable and short-lived for most women, but its intensity varies by life stage.

• Nulliparous women consistently report higher pain scores at insertion than parous women. A prospective study of 732 women published in Contraception found mean pain VAS scores of 65/100 in nulliparous women vs. 39/100 in parous women.
• Postpartum women (4 to 6 weeks after delivery) have a more favorable cervical dilation profile, generally reporting lower insertion pain, though expulsion risk is higher (see below).
• Cramping in the first 24 to 48 hours after insertion affects the majority of users. Ibuprofen 600 mg taken one hour before the procedure reduces but does not eliminate this pain.

Ovarian Cysts: How Common, and Do They Resolve?

Functional ovarian cysts are detected by ultrasound in about 12% of Mirena users at any given time, per the prescribing information. Most resolve spontaneously within three months and rarely require intervention. Kyleena carries a similar risk. These are follicular cysts driven by the local hormone suppression of ovulation at the ovarian level, not true pathological cysts, and women should not confuse them with ovarian cancer or endometriosis-related cysts.

Expulsion Rates: What the Numbers Mean by Life Stage

Expulsion, meaning the IUD partially or fully leaving the uterus, is the most common reason for unplanned removal in the first year. The overall first-year expulsion rate across pooled trial data sits at approximately 2 to 10 per 100 women, with the wide range reflecting the population studied.

Postpartum Insertion and Higher Expulsion Risk

Immediate postpartum insertion (within 10 minutes of placental delivery) carries a first-year expulsion rate of roughly 24% compared with approximately 5% at interval insertion. The ACOG Practice Bulletin on Long-Acting Reversible Contraception notes that despite this higher expulsion rate, immediate postpartum insertion is still recommended because it guarantees access to contraception before hospital discharge, when many women do not return for follow-up.

Nulliparous Women and Expulsion

Nulliparous women have a higher expulsion rate than parous women, though the absolute difference is smaller than many clinicians assume. A large Norwegian registry study of 45,093 IUD users found nulliparous women had an expulsion rate roughly twice that of parous women over five years, but absolute rates remained low enough that IUD use is still endorsed for this group by ACOG and the CDC Medical Eligibility Criteria.

Uterine Perforation: Rare but Serious

Perforation occurs when the IUD partially or fully penetrates the uterine wall at insertion. The ECUD (Intrauterine Contraceptive Devices in Users of Different Ages) study, a prospective European cohort of 61,448 women, reported a perforation rate of 1.4 per 1,000 insertions overall. Breastfeeding women had a rate approximately six times higher (6.3 per 1,000), likely because postpartum uterine involution and estrogen deficiency reduce uterine wall thickness and tone.

Perforation is usually discovered incidentally on a follow-up ultrasound after a woman cannot feel her strings. It rarely causes immediate symptoms, which is precisely why routine string checks at four to six weeks post-insertion matter. If the device perforates into the peritoneal cavity, surgical removal is required.

A practical life-stage framework for perforation counseling:

| Life Stage | Relative Perforation Risk | Notes | |---|---|---| | Reproductive-age, not breastfeeding | ~1 per 1,000 | Baseline | | Breastfeeding (any time postpartum) | ~6 per 1,000 | Counsel explicitly | | Postpartum, not breastfeeding | ~1.5 per 1,000 | Slightly elevated | | Perimenopause (estrogen-low state) | Limited data; may be elevated | Atrophic uterus is thinner |

Perimenopausal women represent a real evidence gap. Trial data on IUD insertion in women over 45 who are approaching menopause are sparse, and thinner, more atrophic uterine walls may increase perforation risk. A clinician inserting a Mirena for heavy menstrual bleeding or endometrial protection in this group should proceed with care and ideally use ultrasound guidance.

Hormonal Side Effects: Mood, Acne, Libido

The levonorgestrel in a hormonal IUD is largely locally active, but systemic absorption is measurable. Mirena produces mean serum LNG concentrations of approximately 150 to 200 pg/mL in the first year, which is far lower than oral contraceptive pills but not zero. Kyleena produces lower serum levels still.

Mood and Depression

The largest pharmacoepidemiological study examining hormonal contraception and depression was the Danish cohort study by Skovlund et al., published in JAMA Psychiatry in 2016. It followed 1,061,997 Danish women for over 13 years and found that levonorgestrel IUD users had a relative risk of first antidepressant use of 1.4 compared with non-users. The absolute increase was small, and causality is unproven. Still, women who report mood changes on other progestin-containing contraceptives deserve a thoughtful conversation before IUD insertion.

Acne and Androgenic Effects

Levonorgestrel has mild androgenic activity. Women with PCOS or androgenic acne who are switching from combined oral contraceptives (which suppress androgens) to a levonorgestrel IUD may notice a return or worsening of acne, because they lose the anti-androgenic benefit of ethinyl estradiol and sex-hormone-binding globulin elevation. This is particularly relevant for women with PCOS, where baseline androgen excess already drives skin symptoms. The IUD itself does not actively worsen androgens beyond removing the COCP's suppressive effect.

Libido

Decreased libido is listed in the prescribing information with an incidence of approximately 7% in Mirena trials. The mechanism may involve both direct androgenic activity on SHBG (lower SHBG means more free testosterone, which might be libido-neutral or even positive) and a central progestogenic effect. Data here are weak, and no randomized controlled trial has specifically examined HSDD as an outcome of levonorgestrel IUD use in women.

Pregnancy and Lactation Safety

Pregnancy: Contraindicated. The levonorgestrel IUD must not be inserted in a woman with a confirmed or suspected pregnancy. If pregnancy occurs with the IUD in situ (a rare event given the <1% annual failure rate), there is an increased risk of spontaneous abortion, septic abortion, and preterm delivery. ACOG advises removing the IUD if the strings are visible and the woman wishes to continue the pregnancy, while acknowledging that removal itself carries a risk of pregnancy loss.

The small amounts of levonorgestrel released locally do not carry a known teratogenic signal in the limited published data, but this scenario should always be managed jointly by the patient and her clinician.

Ectopic pregnancy risk: Women who become pregnant with any IUD in place have a higher proportion of ectopic pregnancies. The absolute rate of ectopic pregnancy is actually lower in IUD users than in women using no contraception, because the IUD suppresses total pregnancy rates so effectively. The FDA label for Mirena states that approximately half of pregnancies that occur during use may be ectopic.

Lactation: Levonorgestrel IUDs are generally considered compatible with breastfeeding. The CDC Medical Eligibility Criteria (MEC) assigns a Category 2 (advantages outweigh risks) for insertion between four and six weeks postpartum in breastfeeding women, and Category 1 (no restriction) after six weeks. Small amounts of LNG are transferred into breast milk, but no adverse effects on infant development have been demonstrated in follow-up studies of up to five years. Women who want immediate postpartum insertion while breastfeeding should know that perforation risk is elevated and should be counseled accordingly.

Contraception while awaiting insertion: If a woman receives her IUD outside of the first seven days of her menstrual cycle, backup contraception is needed for seven days. If she has had unprotected sex in the preceding five days and the IUD is being inserted as emergency contraception, a copper IUD (not the hormonal IUD) is the appropriate choice, with a failure rate of <0.1% as emergency contraception.

Who Is a Good Candidate, and Who Should Think Twice

Good Candidates by Life Stage

• Reproductive years (18 to 40): Both Mirena and Kyleena are suitable. Mirena is FDA-approved for heavy menstrual bleeding (not just contraception), making it the preferred choice for women with heavy menstrual bleeding or adenomyosis.
• Trying to conceive in the future: Both IUDs are appropriate. Fertility returns quickly after removal, with median time to first ovulation of approximately three months and no evidence of impaired long-term fertility.
• Perimenopause: Mirena offers dual benefit: highly effective contraception (needed until 12 months after the final menstrual period, per standard guidance) and endometrial protection if systemic estrogen is added for menopausal symptoms. The Menopause Society endorses LNG-IUS as a valid progestogen component of menopausal hormone therapy.
• Postpartum women: Both are appropriate, though the higher expulsion rate at immediate postpartum insertion requires explicit counseling.

Women Who Should Consider Alternatives

• Women with current breast cancer or a personal history of breast cancer should not use the hormonal IUD. The WHO MEC assigns a Category 4 (unacceptable risk) for current breast cancer.
• Women with unexplained vaginal bleeding before evaluation.
• Women with uterine anomalies (significant fibroids distorting the cavity, bicornuate uterus) where correct placement may be impossible.
• Women who have had pelvic inflammatory disease within the past three months, or who are at high risk of STIs without a stable, mutually monogamous relationship.
• Women with Wilson's disease (copper IUD contraindicated; hormonal IUD is fine, but this is a common mix-up worth naming).

Rare and Serious Adverse Events: FAERS Data and Post-Market Literature

The FDA Adverse Event Reporting System (FAERS) contains thousands of reports for both Mirena and Kyleena. The most clinically significant rare events include:

Embedment: Partial penetration of the myometrium, distinct from full perforation. Rates are not well-quantified in prospective trials but appear in case series. Typically found at removal when strings cannot be visualized.

Actinomyces colonization: Incidental finding on Pap smear in IUD users. Symptomatic actinomycosis is exceedingly rare. Asymptomatic colonization does not require IUD removal per current guidance from ACOG.

Pelvic inflammatory disease (PID): Risk is elevated in the first 20 days after insertion, likely reflecting insertion-related contamination rather than the device itself. A systematic review in the American Journal of Obstetrics and Gynecology quantified this early insertion-related PID risk at roughly six times baseline in the first three weeks, returning to baseline thereafter. Screening for gonorrhea and chlamydia before insertion reduces this risk.

Intravascular or device failure: Extremely rare. Device fracture during removal has been reported in FAERS but does not appear in controlled trial safety databases at meaningful frequencies.

Specific Populations: PCOS, Endometriosis, and Fibroids

PCOS

Women with PCOS who need contraception can use the levonorgestrel IUD. It does not address the metabolic features of PCOS (insulin resistance, dyslipidemia, hyperandrogenism) and may allow acne to return if switching from a combined oral contraceptive. Women with PCOS who have been using the pill partly for androgen suppression should plan for a topical or oral adjunct for acne if they make this switch. Mirena used specifically for endometrial protection in anovulatory PCOS (to prevent endometrial hyperplasia) is a recognized off-label but evidence-supported use. A 2022 systematic review in Fertility and Sterility confirmed LNG-IUS effectively prevents endometrial hyperplasia in anovulatory women.

Endometriosis

The levonorgestrel IUD reduces endometriosis-related dysmenorrhea and may slow lesion progression, though it does not eliminate existing lesions. The evidence is strongest for pain reduction rather than lesion regression. Women with endometriosis considering the IUD for symptom management rather than contraception should understand that effect onset takes three to six months. ACOG Practice Bulletin 114 on endometriosis includes LNG-IUS as a medical management option.

Uterine Fibroids

Fibroids that do not distort the uterine cavity are not a contraindication. Mirena reduces heavy bleeding associated with fibroids, though it does not shrink fibroid size. Women with submucous fibroids (Type 0 or 1, protruding into the cavity) have higher expulsion rates and may not be suitable candidates.

Side-Effect Incidence Comparison: Mirena vs. Kyleena

| Side Effect | Mirena (52 mg LNG) | Kyleena (19.5 mg LNG) | Source | |---|---|---|---| | Irregular bleeding at 3 months | ~70% | ~65% | FDA labels | | Amenorrhea at 12 months | ~20% | ~12% | FDA labels | | Ovarian cysts | ~12% point prevalence | ~22% | FDA labels | | Expulsion (year 1, interval) | ~3 to 5% | ~3 to 5% | Pooled trials | | Acne (any) | ~6 to 15% | ~15% | FDA labels | | Headache | ~8% | ~8% | FDA labels | | Decreased libido | ~7% | ~5% | FDA labels | | Perforation | ~1 per 1,000 | ~1 per 1,000 | ECUD study |

Kyleena has a higher reported rate of ovarian cysts than Mirena. The Kyleena prescribing label reports follicular ovarian cysts in approximately 22% of users, compared with 12% for Mirena. The likely explanation is that Kyleena's lower systemic dose provides less suppression of the hypothalamic-pituitary-ovarian axis, allowing more follicular development that stalls before rupturing.

Evidence Gaps and What Is Extrapolated

Women have been under-represented in general pharmacology research, but IUD trials have enrolled predominantly women by necessity. Still, meaningful gaps remain:

• Perimenopausal women over 48: Almost no registration-trial data. Extrapolation from reproductive-age data is standard but unvalidated.
• Women with chronic pelvic pain conditions: Insertion pain and post-insertion cramping in women with endometriosis or adenomyosis may be substantially higher than trial averages, which excluded severe disease.
• Mood and psychiatric outcomes: The Danish cohort (Skovlund 2016) is the best available data, but it was observational. No randomized trial has tested mood endpoints for the LNG-IUD specifically, and confounding by indication remains a real concern.
• Long-term lactation outcomes: Studies following infants of IUD-using mothers beyond 12 months are sparse. Current reassurance about safety rests on short-term data and the low absolute serum LNG levels measured in breast milk.

As WomanRx reviewer Rachel Goldberg, MD, puts it: "The bleeding pattern change in the first three to six months is the single biggest driver of early removal, and most of those removals happen because no one prepared the patient for it at the time of insertion. A five-minute counseling conversation prevents the majority of regret-driven explants."